Retatrutide Tracking Considerations: Emerging Triple-Agonist Research

Retatrutide (LY3437943, Eli Lilly) is an investigational peptide that activates THREE incretin receptors: GLP-1 (like semaglutide), GIP (added by tirzepatide), and GLUCAGON (the new addition). The glucagon arm is the differentiating feature — it increases energy expenditure and lipolysis in addition to the satiety and glucose-control effects of the other two arms. Published Phase 2 trials reported mean weight loss of approximately 24% at 48 weeks at the highest dose tested — substantially higher than the ~15% reported for semaglutide and ~21% for tirzepatide in comparable trials. Retatrutide is NOT FDA approved as of this writing and remains in clinical trials. Research log tracking focuses on dose escalation week-by-week, side-effect onset and resolution, weight trajectory, and any markers researchers are personally monitoring. This content is for educational and research-tracking purposes only and does not constitute medical advice.

SEMAGLUTIDE (Wegovy, Ozempic): GLP-1 agonist only. Slows gastric emptying, increases satiety, lowers glucose. Approved for type 2 diabetes and chronic weight management. Reported weight loss ~15% at 68 weeks. TIRZEPATIDE (Mounjaro, Zepbound): dual GLP-1 + GIP agonist. The GIP arm adds glucose-dependent insulinotropic effects and additional metabolic actions. Reported weight loss ~21% at 72 weeks. RETATRUTIDE: triple GLP-1 + GIP + GLUCAGON. The glucagon arm uniquely increases energy expenditure (so total energy balance favors weight loss even more), increases lipolysis, and improves liver fat in published trials. The glucagon agonism also adds heart-rate elevation as a side effect, slightly more than GLP-1 agonists alone. Each successive receptor addition has expanded the metabolic profile and the magnitude of effect — but also the breadth of potential side effects.

Phase 2 trials of retatrutide used progressive dose escalation starting at 2 mg once weekly subcutaneous injection. Doses tested included 1, 4, 8, and 12 mg cohorts with maintenance at the target dose. Researchers tracking similar protocols typically log: weekly DOSE, INJECTION DATE AND SITE (rotation across abdomen, thigh, and arm quadrants), AE ONSET (nausea, decreased appetite, fatigue typically peak 24-48h post-dose, declining over 5-7 days), AE RESOLUTION (most early AEs resolve before the next dose at lower doses; persist longer at higher doses), WEIGHT (typically twice weekly at same time, same scale, same conditions), and any LAB VALUES being personally monitored (some researchers track hemoglobin A1c, lipid panel, liver enzymes if accessible). The Eli Lilly publications report tolerability across the cohorts with the highest doses producing the largest weight loss but also the highest side-effect incidence.

Retatrutide trials reported a side-effect profile similar to GLP-1 agonists with some unique additions from the glucagon arm. GI EFFECTS (nausea, vomiting, diarrhea, constipation): dose-dependent, peak in first 1-2 days post-injection, decline over 5-7 days at lower doses, persist longer at higher doses. SATIETY AND APPETITE SUPPRESSION: profound at higher doses, including reports of food aversion. HEART RATE: average increase of 4-10 bpm at higher doses, more pronounced than GLP-1-only agonists due to glucagon-driven sympathetic activation. RESTING ENERGY EXPENDITURE: increased meaningfully, contributing to the larger weight loss vs single or dual agonists. HEPATIC LIPID: significant reductions reported in trials, suggesting potential application in NASH and related conditions. INJECTION SITE: typical local reactions (redness, itching, sometimes small wheals) usually resolving in 24-72 hours. Researchers tracking their personal logs typically note onset time and severity on a 0-10 scale to inform dose-escalation pacing.

Researchers personally tracking retatrutide protocols typically maintain a structured log with the following variables: DATE AND TIME OF INJECTION, DOSE in mg, INJECTION SITE (quadrant tracking to avoid lipohypertrophy), CONCENTRATION of reconstituted peptide, RESEARCH BATCH IDENTIFIER. WEIGHT: same scale, same time of day, ideally morning post-void. WAIST CIRCUMFERENCE: weekly. RESTING HEART RATE: daily morning resting HR (taken in supine position before getting up). BLOOD PRESSURE: weekly. SIDE EFFECTS: onset, severity 0-10, duration in hours. SLEEP, ENERGY, APPETITE: 0-10 daily ratings. ANY LABS personally monitored. APP-BASED TRACKING reduces transcription error and produces graphical trends across the protocol period. This content is for educational and research-tracking purposes only.

Retatrutide research peptides are typically supplied as a lyophilized powder. Reconstitution with bacteriostatic water (containing 0.9% benzyl alcohol as a preservative) preserves the peptide for approximately 28 days refrigerated 2-8°C, per general peptide stability principles — though specific manufacturer guidance should always be followed. Once reconstituted, mark the date on the vial. Lyophilized powder stored at -20°C or below in original packaging is stable for the labeled shelf life. Avoid freeze-thaw cycles after reconstitution. Light-sensitive peptides should be stored in opaque or amber vials. Common volume calculations: e.g., 10 mg lyophilized peptide reconstituted in 2 mL bacteriostatic water yields 5 mg/mL concentration; a 2 mg target dose is 0.4 mL drawn. Reconstitution calculators in tracking apps simplify the dose math and reduce error. This content is for educational and research purposes only.

Dosed supports researcher-managed tracking of investigational peptide protocols including retatrutide. Log dose, injection site, weight, vitals, and side effects; the app produces trend visualizations, side-effect heat maps across the protocol period, and reconstitution calculators that match the peptide concentration to the target dose. Dose-escalation schedules can be templated based on published trial protocols. This content is for educational and research-tracking purposes only and does not constitute medical advice.